FDA's Gottlieb Looks To Resuscitate Competition For Shortage Drugs
Executive Summary
FDA's new commissioner, Scott Gottlieb, is looking to go beyond the agency's ad hoc responses to sterile injectables drug shortages and find ways to prevent such shortages by stirring up more competition under Hatch-Waxman. Meanwhile, manufacturers are looking for deeper commitments from group purchasing organizations to buy such drugs, which would enable greater investments in facilities and equipment.
You may also be interested in...
Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing
Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.
Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing
Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.
Manufacturers Urged To Prevent Drug Shortages By Reducing Quality Risks
As the main cause of drug shortages is poor manufacturing quality, the best way to prevent them is to get ahead of the curve on quality, says a Pew/ISPE industry survey report.